Annovis Bio, Inc. 8-K

What Happened

• On May 15, 2026, Annovis Bio, Inc. (ANVS) announced and furnished a press release reporting its earnings and financial results for the quarter ended March 31, 2026.
• The company filed a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) and attached the press release as Exhibit 99, which is incorporated by reference.

Key Details

• Filing date: May 15, 2026.
• Reporting period: Quarter ended March 31, 2026.
• Form 8‑K Item reported: 2.02 (Results of Operations and Financial Condition).
• Press release furnished as Exhibit 99 with the filing.

Why It Matters

• This 8‑K provides a timely public disclosure of Annovis Bio’s quarterly results; investors should review the attached press release for specifics on earnings, revenue, cash position, and any management commentary.
• The filing does not announce executive changes, mergers, or other corporate actions—its focus is the company’s quarterly operating and financial results.
• For a fuller view of financial statements and formal disclosures, investors should look for the related quarterly report (e.g., Form 10‑Q) or company updates that may follow.